Merck + Co., Inc.

Other

Joanne Waldstreicher

Elizabeth Stoner

Keith D Kaufman

Glenn J Gormley

Carl M Mendel

Georgianna S Harris

Vivian L Fuh

Michel A Pontari

Daniel Z Wang

Harry A Guess

Jay Dee Pearson

Curtis J Nickel

Stanley G Spence

Briggs W Morrison

Mark A Cukierski

A tachykinin antagonist is useful, alone or in conjunction with other agents, for altering circadian rhythmicity and alleviating circadian rhythm disorders and for enhancing and improving the quality of sleep.

Prevention or treatment of insomnia with a neurokinin-1 receptor antagonist

A COX-2 selective inhibiting drug is disclosed as useful in treating or preventing prostate cancer. The compound is used alone or in combination with other drugs.

Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug

The use of a COX-2 selective inhibitor for the treatment of chronic prostatitis or chronic pelvic pain syndrome is disclosed.

Method for treating chronic prostatitis or chronic pelvic pain syndrome

The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5&agr;-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.

Method of treating seborrhea with 5-&agr; reductase inhibitors

Method of improving in-vitro fertilization

Enhancement of sleep with a tachykinin antagonist

The present invention provides for the combined use of 5&agr;-reductase inhibitors together with calcium channel blockers for the treatment of benign prostatic hyperplasia (BPH), prostate cancer, prostatitis, hematuria, and other androgen related disorders, including prostatitis and the prevention of prostate cancer. This invention provides a method of treatment which is useful in the treatment of benign prostatic hyperplasia, prostatitis, and/or the prevention and treatment of prostatic cancer, as well as in the treatment of prostatitis and hematuria. This invention also provides a pharmaceutical composition which is useful in the treatment of benign prostatic hyperplasia, prostatitis, hematuria and/or the prevention and treatment of prostatic cancer, wherein the pharmaceutical composition comprises the combination of a 5&agr;-reductase inhibitor and a calcium channel blocking agent.

Method for treating androgen-related conditions

Method of treating acne with 5-&agr; reductase inhibitors

A tachykinin receptor antagonist, in particular a neurokinin-1 receptor antagonist, is useful for the treatment or prevention of chronic nonbacterial prostatitis and/or prostatodynia.

Method for treating or preventing chronic nonbacterial prostatitis and

The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor such as finasteride, in a dosage amount under 5 mgs/day.

Method of treating androgenic alopecia with 5.alpha.-reductase inhibitors

The present invention provides for a method of inhibiting bone loss in a subject in need of such treatment comprising administration to the subject of a therapeutically effective amount of a compound of structural formula I: ##STR1## The present invention further provides for a method for treating and preventing osteoporosis and osteopenia and other diseases where inhibiting bone loss may be beneficial, including: Paget's disease, malignant hypercalcemia, periodontal disease, joint loosening and metastatic bone disease, comprising administration of therapeutically effective amount of a compound of structural formula I to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for inhibiting bone loss and treating or preventing osteoporosis and osteopenia.

Methods and compositions for preventing and treating bone loss

This invention is concerned with the prevention of precipitated acute urinary retention in a subject male susceptible thereto by the administration of an inhibitor of 5.alpha.-reductase to the subject. The present invention also provides for a method of reducing the risk of precipitated acute urinary retention by the administration of a 5.alpha.-reductase inhibitor to the subject at risk therefor.

Prevention of precipitated acute urinary retention

The present invention provides for a method of treating polycystic ovary syndrome in a subject in need of such treatment comprising the administration of a therapeutically effective amount of a compound of structural formula I: ##STR1## to the subject. The present invention further provides for a method for improving fertility and the response to in vitro fertilization (I.V.F.), comprising administration of therapeutically effective amount of compound of structural formula I to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating polycystic ovary syndrome or for improving fertility or the response to in vitro fertilization (I.V.F.).

Methods for treating polycystic ovary syndrome

The present invention provides for a method of treating preterm labor in a subject in need of such treatment comprising administration of a therapeutically effective amount of an inhibitor of 5.alpha.-reductase type 1 to the subject. The present invention further provides for a method of preventing premature labor in a subject susceptible thereto comprising administration of a labor-preventive amount of an inhibitor of 5.alpha.-reductase type 1 to the subject. Further, the present invention also relates to a method of reducing the risk of premature labor in a subject at risk therefor. The present invention also provides for a method for stopping labor preparatory (i.e., prior) to Cesarean delivery in a subject in need of such treatment comprising administration of a therapeutically effective amount of an inhibitor of 5.alpha.-reductase type 1 to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating pre-term labor and for stopping labor preparatory to Cesarean delivery.

Growing community of inventors

Scotch Plains, NJ, United States of America

Joanne Waldstreicher